Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Harvard Business School
Cipla
Julphar
Deloitte
Citi
McKesson
Novartis
Johnson and Johnson
Teva

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,754,109

« Back to Dashboard

Which drugs does patent 8,754,109 protect, and when does it expire?

Patent 8,754,109 protects ESBRIET and is included in two NDAs.

This patent has thirty-three patent family members in twenty-seven countries.
Summary for Patent: 8,754,109
Title:Pirfenidone therapy and inducers of cytochrome P450
Abstract: The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking.
Inventor(s): Bradford; Williamson Z. (Ross, CA), Szwarcberg; Javier (San Francisco, CA)
Assignee: Intermune, Inc. (Brisbane, CA)
Application Number:13/513,472
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,754,109

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Genentech Inc ESBRIET pirfenidone CAPSULE;ORAL 022535-001 Oct 15, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY AVOIDING SMOKING OR BY AVOIDING ANOTHER STRONG CYP1A2 INDUCER ➤ Subscribe
Genentech Inc ESBRIET pirfenidone TABLET;ORAL 208780-001 Jan 11, 2017 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Genentech Inc ESBRIET pirfenidone TABLET;ORAL 208780-003 Jan 11, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,754,109

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
10250378Mar 3, 2010
Canada2710014Oct 8, 2010
PCT Information
PCT FiledDecember 03, 2010PCT Application Number:PCT/US2010/058936
PCT Publication Date:June 09, 2011PCT Publication Number: WO2011/069089

Non-Orange Book US Patents Family Members for Patent 8,754,109

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,084,475 Pirfenidone therapy and inducers of cytochrome P450 ➤ Subscribe
8,648,098 Pirfenidone therapy and inducers of cytochrome P450 ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,754,109

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Eurasian Patent Organization 026869 ➤ Subscribe
European Patent Office 2308491 ➤ Subscribe
European Patent Office 2377537 ➤ Subscribe
European Patent Office 2506849 ➤ Subscribe
Spain 2395159 ➤ Subscribe
Georgia, Republic of P20166426 ➤ Subscribe
Hong Kong 1151725 ➤ Subscribe
Japan 2012153734 ➤ Subscribe
Croatia P20110853 ➤ Subscribe
Israel 219056 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Baxter
Medtronic
US Department of Justice
Cipla
Fuji
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot